Cytosorbents CORP Form 4 insider transactions

Kathleen Bloch, CFO of Cytosorbents, reports the acquisition of 65,000 restricted stock units and 87,000 stock options.

Director Michael G. Bator reports the acquisition of 44,000 stock options in Cytosorbents Corp.

Vincent Capponi, President and COO of Cytosorbents Corp, reports the acquisition of 81,000 shares of common stock and 101,000 stock options.

Director Jiny Kim reports the acquisition of 22,000 stock options in Cytosorbents Corp on April 2, 2024, according to a Form 4 filing.

Phillip P. Chan, CEO of Cytosorbents Corp, reports the acquisition of 96,000 shares of common stock and 124,000 stock options.

Efthymios Deliargyris, Chief Medical Officer of Cytosorbents Corp, acquired 47,088 stock options as part of a voluntary salary reduction program.

Vincent Capponi, President and COO of Cytosorbents Corp, acquired 48,923 stock options as part of a voluntary salary reduction program.

Kathleen P. Bloch, CFO of Cytosorbents Corp, acquired 49,038 stock options as part of a voluntary salary reduction program.

Cytosorbents CEO Phillip P. Chan acquired 129,998 stock options on March 29, 2024, as part of a voluntary salary reduction program.